文献速递乳腺外科

腋窝超声在SOUND试验合格乳腺癌患者中的性能评估

Evaluation of axillary ultrasound performance on Sentinel Node versus Observation after Axillary Ultrasound (SOUND) trial-eligible patients.
PubMed 文献 · Surgery · 2025-12-24

本研究回顾性分析2015至2023年符合SOUND试验标准的263例乳腺癌患者,评估术前腋窝超声性能。结果显示假阴性率13.5%,敏感度23%,特异度94%,阴性预测值88%。肿瘤每增大1cm,假阴性腋窝超声的比值比增加46%。

要点

  • 腋窝超声假阴性率13.5%,与SOUND试验的13.7%相近。
  • 肿瘤每增大1cm,假阴性腋窝超声风险增加46%。
  • T1mi/T1a和T1b肿瘤假阴性率较低,可考虑省略前哨淋巴结活检。

核心结论

  • 腋窝超声的高特异度和阴性预测值提示,在术前腋窝超声阴性的小乳腺癌中省略前哨淋巴结活检是合理的,尤其是T1mi/T1a和T1b肿瘤。

研究设计与样本

  • 回顾性研究,纳入2015至2023年符合SOUND试验标准的263例患者,其中223例接受了前哨淋巴结活检。

主要发现

  • 总体假阴性腋窝超声率为13.5%。
  • 腋窝超声敏感度23%,特异度94%,阳性预测值37%,阴性预测值88%。
  • 不同分子亚组间特异度有显著差异(P = .005)。
  • 病理T分组间假阴性率有显著差异(P = .015):T2为31%,T1c为13%,T1b为11%,T1mi/T1a为0%。
  • 多变量分析显示肿瘤每增大1cm,假阴性腋窝超声的比值比为1.46(P = .018)。

临床怎么用

  • 对于术前腋窝超声阴性的小乳腺癌患者,尤其是T1mi/T1a和T1b肿瘤,可考虑省略前哨淋巴结活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Sentinel Node versus Observation after Axillary Ultrasound (SOUND) trial suggested that sentinel lymph node biopsy could be omitted in small breast cancers with negative axillary ultrasound, despite 13.7% of preoperative axillary ultrasound being falsely negative when validated on sentinel lymph node biopsy. Our aim was to evaluate the performance of axillary ultrasound in our patient population using SOUND trial criteria. METHODS: A retrospective review was performed between 2015 and 2023 of SOUND trial-eligible patients. Two subgroup univariate analyses, pathologic T classification group and molecular subgroup, were performed comparing preoperative axillary ultrasound performance metrics, demographics, and tumor characteristics. Multivariate analysis was performed to predict false-negative axillary ultrasound. RESULTS: 263 patients were SOUND trial-eligible, whereas only 223 had a sentinel lymph node biopsy. Overall, this study was similar to the SOUND trial in terms of demographics and tumor characteristics, as well as false-negative axillary ultrasound (13.5%). The remaining performance metrics of preoperative axillary ultrasound were sensitivity (23%), specificity (94%), positive predictive value (37%), and negative predictive value (88%). There were significant differences in specificity (P = .005) among molecular subgroups (Luminal/HER2-, HER2/neu+, and triple-negative). False-negative axillary ultrasound was significantly different (P value .015) when comparing pathologic T group (31% T2, 13% T1c, 11% T1b, and 0% T1mi/T1a). Multivariate analysis demonstrated that each 1-cm increase in tumor size was associated with 46% higher odds of a false-negative axillary ultrasound (odds ratio 1.46 per cm, P = .018). CONCLUSIONS: The high specificity and negative predictive value of axillary ultrasound suggests that foregoing sentinel lymph node biopsy in small breast cancers with negative preoperative AUS is reasonable, especially in patients with T1mi/T1a and T1b tumors.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Stephens KR, Wilson M, Xu M, et al. Evaluation of axillary ultrasound performance on Sentinel Node versus Observation after Axillary Ultrasound (SOUND) trial-eligible patients. Surgery. 2025. PMID: 41448967. doi:10.1016/j.surg.2025.109927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。